| 1. |
van Geldorp MW, Eric Jamieson WR, Kappetein AP, et al. Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: weighing lifetime anticoagulant-related event risk against reoperation risk. J Thorac Cardiovasc Surg, 2009, 137(4): 881-886.
|
| 2. |
Takkenberg JJ, van Herwerden LA, Eijkemans MJ, et al. Evolution of allograft aortic valve replacement over 13 years: results of 275 procedures. Eur J Cardiothorac Surg, 2002, 21(4): 683-691.
|
| 3. |
Rahimtoola SH. Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol, 2010, 55(22): 2413-2426.
|
| 4. |
Isaacs AJ, Shuhaiber J, Salemi A, et al. National trends in utilization and in-hospital outcomes of mechanical versus bioprosthetic aortic valve replacements. J Thorac Cardiovasc Surg, 2015, 149(5): 1262-1269.
|
| 5. |
Wring group members, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation, 2010, 121(7): e46-e215.
|
| 6. |
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol, 2017, 70(2): 252-289.
|
| 7. |
Wang Y, Chen S, Shi JW, et al. Mid- to long-term outcome comparison of the Medtronic Hancock II and bi-leaflet mechanical aortic valve replacement in patients younger than 60 years of age: a propensity-matched analysis. Interact Cardiovasc Thorac Surg, 2016, 22(3): 280-286.
|
| 8. |
Wang Y, Chen S, Hu XJ, et al. Mid-to long-term clinical outcomes of Hancock II bioprosthesis in Chinese population. Chin Med J (Engl), 2015, 128(24): 3317-3323.
|
| 9. |
Gaur P, Kaneko T, McGurk S, et al. Mitral valve repair versus replacement in the elderly: short-term and long-term outcomes. J Thorac Cardiovasc Surg, 2014, 148(4): 1400-1406.
|
| 10. |
Mihos CG, Pineda AM, Capoulade R, et al. A systematic review of mitral valve repair with autologous pericardial leaflet augmentation for rheumatic mitral Regurgitation. Ann Thorac Surg, 2016, 102(4): 1400-1405.
|
| 11. |
Attizzani GF, Ohno Y, Capodanno D, et al. Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry. JACC Cardiovasc Interv, 2015, 8(1 Pt A): 74-82.
|
| 12. |
Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet, 2015, 385(9986): 2477-2484.
|
| 13. |
Kaneko T, Cohn LH, Aranki SF. Tissue valve is the preferred option for patients aged 60 and older. Circulation, 2013, 128(12): 1365-1371.
|
| 14. |
Jorge-Herrero E, Garcia Paez JM, Del Castillo-Olivares Ramos JL. Tissue heart valve mineralization: Review of calcification mechanisms and strategies for prevention. J Appl Biomater Biomech, 2005, 3(2): 67-82.
|
1/5
WeChat